Helping validated therapeutic innovations reach more patients.
Software & Solutions
Severan provides biopharma and medtech companies with tailored, non-dilutive financing to power commercialization — enabling innovations to reach patients faster and at greater scale.
Non-dilutive financing for biopharma and medtech, built around what comes after the science.
We provide structured, non-dilutive capital alongside commercial, scientific, and access expertise, so founders can accelerate adoption without giving up equity, IP, or control of their company's direction.
.svg)
Funding without equity dilution or loss of IP ownership
Bring life-saving and life-improving products to patients faster
Scale access to innovative therapeutics, diagnostics, and medical devices
Preserve strategic independence while accelerating adoption
.svg)
Enhanced credibility from deep sector expertise
Identify the value that’s held in the margin through expert vetting
Partner with commercial, scientific, and access experts
Leverage credible diligence even for therapeutic areas outside the focus of institutional platforms
Purpose-driven capital with measurable impact
Severan Capital originates revenue-based investments into biomedical innovations with high potential for patient impact.
Built on alignment
Severan investments strategically align innovators and investors, linking patient impact with financial returns:
Returns scale as products are adopted by doctors and patients
Financial performance reflects patient access, not corporate exits
No trade-off between patient impact and investor outcomes
Learn more
Learn more
“Our tailored, asset-backed financing propels companies through critical inflection points without a maturity date or financial covenants that increase financial risk. Structure and timing are flexible to meet the situational needs of each innovator.“
Exposure where it compounds
Our model provides investors exposure to life sciences growth at the point where
Patient benefit
Commercial execution
Financial returns meet
Explore Severan’s Investors Page
Learn more
Financing structured around The inflection point.
Severan's experts partner with life sciences companies to design non-dilutive financings tailored to the moment — whether that's a commercial launch, a label expansion, or a pivotal scale-up.
Our financings are designed for:
Late-clinical to commercial-stage biopharma, medtech, and diagnostics companies.
Companies with near-term or existing revenues and clear product-level cash flows
Management teams seeking non-dilutive growth capital without loss of strategic control
Ask us a question
Learn more
A Team Purpose-Built to Underwrite Life Sciences Commercial Risk
Severan Capital was founded to create new pathways to invest in the value of biomedical innovation and to empower scientific innovators seeking to preserve strategic control.
Built by Industry Veterans
Our team is led by experienced operators and experts who have worked across the biopharma and medtech sectors.
We diligence and underwrite risks associated with commercial launches, market expansion, and lifecycle investments.
We have extensive experience vetting the essential elements of commercial success, including go-to-market strategy, competitive dynamics, reimbursement risks, and policy evolution.
Ask us a question
Learn more
Max Hunt
Founder & CEO
The Commercialization Capital Gap
Find clear, straightforward answers to the most common questions about our approach. Severan provides structured, non-dilutive capital to life sciences companies through synthetic capped royalty and revenue-based financing.
Why is there a financing gap in biomedical commercialization?
Where is the funding gap most persistent?
When is revenue financing most attractive?
Why revenue financing vs. equity and debt?
What is royalty financing?
What is synthetic capped royalty financing?
